Home Compare BIIB vs GSK.L
Stock Comparison · Industry comparison · Drug Manufacturers - General

Biogen vs GSK: Which Stock Looks Stronger in 2026?

GSK holds the cleaner structural position, with the lead spread across growth and stability. Biogen does not offset that deficit through any equally strong structural edge elsewhere. The market setup is broadly comparable for both — no clear directional signal from price behavior. The market is not adding a decisive signal either way — the structural read carries the weight.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

This is not just a one-metric split: both growth and stability materially support the lead. The overall score gap is 39 points in favour of GSK plc.

INDUSTRY COMPARISON

Both operate in: Drug Manufacturers - General

This comparison is based on industry proximity, not on functional trajectory similarity. BIIB and GSK.L share the same industry classification.

For a similarity-based comparison, see how Biogen and GSK each position within their functional peer groups in AssetNext.

Peer-Relative Score
BIIB
Biogen Inc.
26
Peer-Score
Signal qualityHigh
vs
GSK.L
GSK plc
65
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

Score differences across key dimensions.

Dimension spread: BIIB vs GSK.L Profitability 0 46 Stability 10 69 Valuation 80 80 Growth 0 71 BIIB GSK.L
Gap Ranking
#1 Growth +71
#2 Stability +59
#3 Profitability +46
#4 Valuation
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for BIIB and GSK.L Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer BIIBGSK.L Relative valuation Structural strength

GSK plc is cheaper, but Biogen Inc. is still stronger.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Growth
GSK plc ranks near the top of the group on growth; Biogen Inc. sits in the weaker half.
Stability
On stability, the gap still runs the same way: GSK plc sits near the top of the group, while Biogen Inc. remains in the weaker half.
Growth — Dominant Gap
BIIB
0
GSK.L
71
Gap+71in favour of GSK.L

One company is still expanding while the other is contracting, which creates a very wide growth split.

What else supports the lead

Stability still reinforces the same direction, which makes the lead look broader across the profile.

What this means for the comparison

The lead is built on both growth and stability, making it broader than a single-dimension result.

Explore full peer positioning in AssetNext

Break down the BIIB vs GSK.L comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Similar growth-and-stability comparisons

Explore how BIIB and GSK.L each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.